Journal Mobile Options
Table of Contents
Vol. 14, No. 4, 2002
Issue release date: November 2002
Dement Geriatr Cogn Disord 2002;14:167–175
(DOI:10.1159/000066022)

Clinical and Neuropathological Correlates of Apolipoprotein E Genotype in Dementia with Lewy Bodies

Singleton A.B. · Wharton A. · O’Brien K.K. · Walker M.P. · McKeith I.G. · Ballard C.G. · O’Brien J. · Perry R.H. · Ince P.G. · Edwardson J.A. · Morris C.M.
aMedical Research Council/University of Newcastle upon Tyne, Centre Development in Clinical Brain Ageing, MRC Building, bDepartment of Old Age Psychiatry, cDepartment of Neuropathology, Institute for Ageing and Health, Newcastle General Hospital, and dInstitute for Human Genetics, International Centre for Life, Newcastle upon Tyne, UK

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Dementia with Lewy bodies (DLB) represents the second commonest cause of dementia in the elderly following Alzheimer’s disease (AD). Whilst the presence of Lewy bodies is essential, DLB shares with AD the presence of senile plaques (SP), but neurofibrillary tangles (NFT) are not a necessary feature. The apolipoprotein E (APO E) ε4 allele is the most consistently associated genetic risk factor for AD and has also been shown to associate with DLB. We have therefore analysed the APO E ε4 allele in a large series of DLB cases coming to autopsy to: (1) determine if the ε4 allele describes a similar risk in DLB development as in AD and (2) determine how APO E ε4 allele status correlates with clinical and neuropathological findings in DLB, and in AD, as an indication of the role of APO E in underlying disease biology. Both DLB and AD share an increased ε4 allele frequency, though in DLB the ε2 allele frequency is not reduced and there is a relative lack of ε4 homozygotes. In contrast to previous studies, no association of the ε4 allele with age at onset or duration of disease was found in either disorders. In DLB cases, overall a significantly shorter duration of illness was observed when compared with AD cases, though no significant effect of the ε4 allele on disease onset or duration was seen. The survival rate was reduced by the presence of the ε4 allele in DLB, as with AD. No effect on SP or NFT counts was seen with the ε4 allele, though DLB cases showed a lower SP burden in addition to the expected lower NFT counts. This study demonstrates that DLB shares the APO ε4 allele with AD as a common risk factor, but that there are differences in the way the ε4 allele affects the phenotypic expression of disease.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen EN, Ballard C, de Vos RA, Wilcock GK, Jellinger KA, Perry RH: Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop. Neurology 1996;47:1113–1124.
  2. McKeith IG, Perry RH, Fairbairn AF, Jabeen S, Perry EK: Operational criteria for senile dementia of the Lewy body type (SDLT). Psychol Med 1992;22:911–922.
  3. Dickson DW, Schmidt ML, Lee VM, Zhao ML, Yen SH, Trojanowski JQ: Immunoreactivity profile of hippocampal CA2/3 neurites in diffuse Lewy body disease. Acta Neuropathol (Berl) 1994;87:269–276.
  4. Perry RH, Irving D, Blessed G, Fairbairn A, Perry EK: Senile dementia of Lewy body type. A clinically and neuropathologically distinct form of Lewy body dementia in the elderly. J Neurol Sci 1990;95:119–139.
  5. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA: Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 1993;261:921–923.
  6. Schellenberg GD, Deeb SS, Boehnke M, Bryant EM, Martin GM, Lampe TH, Bird TD: Association of an apolipoprotein CII allele with familial dementia of the Alzheimer type. J Neurogenet 1987;4:97–108.
  7. Pericak-Vance MA, Bebout JL, Gaskell PC Jr, Yamaoka LH, Hung WY, Alberts MJ, Walker AP, Bartlett RJ, Haynes CA, Welsh KA, Roses AD: Linkage studies in familial Alzheimer disease: Evidence for chromosome 19 linkage. Am J Hum Genet 1991;48:1034–1050.
  8. Saunders AM, Strittmatter WJ, Schmechel D, St George Hyslop PH, Pericak-Vance MA, Joo SH, Rosi BL, Gusella JF, Crapper-MacLachlan DR, Alberts MJ, Hulette C, Crain B, Goldgaber D, Roses AD: Association of apolipoprotein E allele ε4 with late-onset familial and sporadic Alzheimer’s disease. Neurology 1993;43:1467–1472.
  9. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD: Apolipoprotein E: High-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 1993;90:1977–1981.
  10. Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell PC Jr, Rimmler JB, Locke PA, Conneally PM, Schmader KE, Pericak-Vance MA, Roses AD: Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet 1994;7:180–184.
  11. Roses AD: Apolipoprotein E affects the rate of Alzheimer’s disease expression: Beta-amyloid is a secondary consequence dependent on APO E genotype and duration of disease. J Neuropathol Exp Neurol 1994;53:429–437.
  12. Meyer MR, Tschanz JT, Norton MC, Welsh-Bohmer KA, Steffens DC, Wyse BW, Breitner JC: APOE genotype predicts when – not whether – one is predisposed to develop Alzheimer disease. Nat Genet 1998;19:321–322.
  13. Strittmatter WJ, Saunders AM, Goedert M, Weisgraber KM, Dong L-M, Jakes R, Huang DY, Pericak-Vance AM, Schmechel D, Roses AD: Isoform specific interactions of apolipoprotein E with microtubule-associated protein tau: Implications for Alzheimer’s disease. Proc Natl Acad Sci USA 1994;91:11183–11186.
  14. Ma J, Yee A, Brewer B Jr, Das S, Potter H: Amyloid-associated proteins α-1 antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments. Nature 1994;372:92–94.
  15. Rebeck G W, Reiter JS, Strickland DK, Hyman BT: Apolipoprotein E in sporadic Alzheimer’s disease: Allelic variation and receptor interactions. Neuron 1993;11:575–580.
  16. Schmechel DE, Saunders AM, Strittmatter WJ, Crain B, Hulette CM, Joo SH, Pericak-Vance MA, Goldgaber D, Roses AD: Increased amyloid β-peptide deposition as a consequence of apolipoprotein E genotype in late onset Alzheimer’s disease. Proc Natl Acad Sci USA 1993;90:9649–9653.
  17. Bales KR, Verina T, Dodel RC, Du Y, Altstiel L, Bender M, Hyslop P, Johnstone EM, Little SP, Cummins DJ, Piccardo P, Ghetti B, Paul SM: Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat Genet 1997;17:263–264.
  18. Galasko D, Saitoh T, Xia Y, Thal LJ, Katzman R, Hill LR, Hansen L: The apolipoprotein E allele epsilon 4 is overrepresented in patients with the Lewy body variant of Alzheimer’s disease. Neurology 1994;44:1950–1951.
  19. St Clair D, Norrman J, Perry R, Yates C, Wilcock G, Brookes A: Apolipoprotein E epsilon 4 allele frequency in patients with Lewy body dementia, Alzheimer’s disease and age-matched controls. Neurosci Lett 1994;176:45–46.
  20. Arai H, Higuchi S, Muramatsu T, Iwatsubo T, Sasaki H, Trojanowski JQ: Apolipoprotein E gene in diffuse Lewy body disease with or without co-existing Alzheimer’s disease. Lancet 1994;344:1307.
  21. Benjamin R, Leake A, Edwardson JA, McKeith IG, Ince PG, Perry RH, Morris CM: Apolipoprotein E genes in Lewy body and Parkinson’s disease. Lancet 1994;343:1565.
  22. Lamb H, Christie J, Singleton AB, Leake A, Perry RH, Ince PG, McKeith IG, Melton LM, Edwardson JA, Morris CM: Apolipoprotein E and alpha-1 antichymotrypsin polymorphism genotyping in Alzheimer’s disease and in dementia with Lewy bodies. Distinctions between diseases. Neurology 1998;50:388–391.
  23. Lippa CF, Smith TW, Saunders AM, Hulette C, Pulaski-Salo D, Roses AD: Apolipoprotein E-epsilon 2 and Alzheimer’s disease: Genotype influences pathologic phenotype. Neurology 1997;48:515–19.
  24. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939–944.
  25. Roth M, Tym E, Mountjoy CQ, Huppert FA, Hendrie H, Verma S, Goddard R: CAMDEX. A standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia. Br J Psychiatry 1986;149:698–709.
  26. Folstein MF, Folstein SE, McHugh PR: ’Mini-mental state’. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198.
  27. Hachinski VC, Ilief LD, Zilhka E, Du Boulay GH, McAllister VL, Marshall J, Russell RW, Symon L: Cerebral Blood flow in dementia. Arch Neurol 1975;32:632–637.
  28. Hixson JE, Vernier DT: Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990;31:545–548.
  29. Wenham PR, Price WH, Blundell G: Apolipoprotein E genotyping by one-stage PCR. Lancet 1991;337:1158–1159.
  30. Cross RB: Demonstration of neurofibrillary tangles in paraffin sections: A quick and simple method using Palmgren’s technique. Med Lab Sci 1982;39:67–69.
  31. Morris CM, Massey HM, Benjamin R, Leake A, Broadbent C, Griffiths M, Lamb H, Brown A, Ince PG, Tyrer S, Thompson P, McKeith IG, Edwardson JA, Perry RH, Perry EK: Molecular biology of APO E alleles in Alzheimer’s and non-Alzheimer’s dementias. J Neural Transm Suppl 1996;47:205–218.
  32. Payami H, Kaye J, Heston LL, Bird TD, Schellenberg GD: Apolipoprotein E genotype and Alzheimer’s disease. Lancet 1993;342:738.

    External Resources

  33. Borgaonkar DS, Schmidt LC, Martin SE, Kanzer MD, Edelsohn L, Growdon J, Farrer LA: Linkage of late-onset Alzheimer’s disease with apolipoprotein E type 4 on chromosome 19. Lancet 1993;342:625.
  34. Mayeux R, Stern Y, Ottman R, Tatemichi TK, Tang MX, Maestre G, Ngai C, Tycko B, Ginsberg H: The apolipoprotein epsilon 4 allele in patients with Alzheimer’s disease. Ann Neurol 1993;34:752–754.
  35. van Duijn CM, de Knijff P, Cruts M, Wehnert A, Havekes LM, Hofman A, Van Broeckhoven C: Apolipoprotein E4 allele in a population-based study of early-onset Alzheimer’s disease. Nat Genet 1994;7:74–78.
  36. Olichney JM, Galasko D, Salmon DP, Hofstetter CR, Hansen LA, Katzman R, Thal LJ: Cognitive decline is faster in Lewy body variant than in Alzheimer’s disease. Neurology 1998;51:351–357.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50